Great partners bring great possibilities.

We work with partners to bring molecular sensing and diagnostics closer to the point of need, jointly creating value by working together in solving some of the world's greatest challenges. Our be.well™ platform pairs advanced molecular assays with secure cloud-enabled data analytics for real-time disease, pathogen and contaminant diagnoses, detection, and analysis. The rapid, handheld and portable platform can be customized to detect a wide range of diseases as well as applications for veterinary, agricultural, and other industrial markets.

Partner Application

How we partner

Every Alveo partner is unique, but we typically work with organizations in one of two ways:

Supported Partnership

Alveo performs the entire process with market and technical domain expertise from the partner. The partner and Alveo then co-commercialize.

Self Sufficient Partnership

The partner performs research and development, with be.well™ expertise from Alveo. The partner and Alveo then co-commercialize.

Image collage of cow, wheat, test tubes with light blue filter

Partner Spotlight

Alveo’s mission to enable earlier detection of pathogens at the point of need has sparked collaborations with companies in multiple industries.

In collaboration with Alveo, Barbados’ top scientists and life sciences industry leaders are designing new assays in the areas of infectious disease, agriculture, veterinary, food, medicine, and aquaculture testing.

Fraunhofer is a top research organization in Germany, prioritizing key technologies and commercializing findings to drive innovation. Alveo partners with them for veterinary research.

An Italian biotechnology company specializing in innovative laboratory diagnostics, Alifax conducted an external validation of the be.well™ COVID-19 test.

How it works

The following phases encompass an Alveo partnership:

Phase 0

Requirements

Market and product requirements are defined and a product development timeline is established.

Phase 1

Feasibility 1

Assay development begins with primer screening and formulation testing.

Phase 2

Feasibility 2

The assay is transferred to the be.well™ Cartridge, where it is optimized and validated through testing facilitated by our enablement software.

Phase 3

Feasibility 3

Clinical and/or field studies are conducted for assay verification and platform validation.

Phase 4

App Updates

Alveo tailors the app to specific market processes, tests the updated app with partner domain experts, and then launches the updated app in the App Store.

Phase 5

Commercialization

The partner and Alveo work together to provide commercial forecasts to facilitate quarterly production plans. Alveo then manufactures the product. Lastly, a marketing and sales plan is launched.

Become a Partner

Alveo believes that industry leaders should drive the expansion of testing in their respective fields to directly address their greatest needs. We invite companies whose expertise, market reach, and customer insights extend beyond Alveo.